BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 21867623)

  • 21. The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.
    El Bordiny M; Al-Ghandour A; Abo Elwafa RA; Fayed O
    Clin Transl Oncol; 2019 Jul; 21(7):864-873. PubMed ID: 30506133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of WT1 expression in bone marrow of acute leukemia patients with real-time quantitative RT-PCR].
    Gu WY; Chen ZX; Cao XS; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):728-31. PubMed ID: 15730716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
    Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors.
    Ujj Z; Buglyó G; Udvardy M; Beyer D; Vargha G; Biró S; Rejtő L
    Pathol Oncol Res; 2016 Jan; 22(1):217-21. PubMed ID: 26531831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression of WT1 gene in children with acute myeloid leukemia].
    Tang X; Guo X; Yang X; Xiao H; Sun JJ; Yuan LX; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2016 Dec; 18(12):1211-1216. PubMed ID: 27974109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression of FANCG gene in acute myeloid leukemia].
    Duan XL; Wang QL; Wang JG; Wang CY; Fan H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):7-11. PubMed ID: 23484681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation between clinical outcome and WT1 detection after hematopoietic stem cell transplantation in acute leukemia].
    Zhao BR; Tang XW; Cen JN; Jin S; Shi XL; Wei XA; Chang WR; Sun AN; Wu DP
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1375-8. PubMed ID: 21756806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
    Kim HR; Shin JH; Lee JN; Lee EY
    Korean J Lab Med; 2007 Oct; 27(5):305-12. PubMed ID: 18094593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia.
    Garg M; Moore H; Tobal K; Liu Yin JA
    Br J Haematol; 2003 Oct; 123(1):49-59. PubMed ID: 14510942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
    Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fluorescence quantitative PCR detection of WT1 gene expression in peripheral blood of patients with acute leukemias and its clinical implications].
    Bai B; Wang HW; Xu YQ; Yang HN; Qiao ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):610-4. PubMed ID: 16129044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients.
    Cilloni D; Gottardi E; De Micheli D; Serra A; Volpe G; Messa F; Rege-Cambrin G; Guerrasio A; Divona M; Lo Coco F; Saglio G
    Leukemia; 2002 Oct; 16(10):2115-21. PubMed ID: 12357365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia.
    Kim HJ; Choi EJ; Sohn HJ; Park SH; Min WS; Kim TG
    Eur J Haematol; 2013 Nov; 91(5):411-22. PubMed ID: 23826993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].
    Kitamura K; Nakano Y; Watamoto K; Koga D; Naoe T
    Rinsho Ketsueki; 2010 Dec; 51(12):1748-55. PubMed ID: 21258184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia.
    Gaiger A; Schmid D; Heinze G; Linnerth B; Greinix H; Kalhs P; Tisljar K; Priglinger S; Laczika K; Mitterbauer M; Novak M; Mitterbauer G; Mannhalter C; Haas OA; Lechner K; Jäger U
    Leukemia; 1998 Dec; 12(12):1886-94. PubMed ID: 9844919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
    Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
    Malagola M; Skert C; Borlenghi E; Chiarini M; Cattaneo C; Morello E; Cancelli V; Cattina F; Cerqui E; Pagani C; Passi A; Ribolla R; Bernardi S; Giustini V; Lamorgese C; Ruggeri G; Imberti L; Caimi L; Russo D; Rossi G
    Cancer Med; 2016 Feb; 5(2):265-74. PubMed ID: 26715369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.